Harvard Bioscience (FRA:HBI0) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 26, 2026)


FRA:HBI0 Harvard Bioscience Inc FRA:HBI0
48 GF Score
Price €4.08
GF Value €13.30
! 6 Warning Signs
View Full Analysis

What is Harvard Bioscience Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Harvard Bioscience's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

FRA:HBI0 vs FEMY, RVP, MLSS: Margin of Safety % (DCF Earnings Based) Comparison

For the Medical Instruments & Supplies subindustry, Harvard Bioscience's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Harvard Bioscience Margin of Safety % (DCF Earnings Based) vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Harvard Bioscience's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Harvard Bioscience's Margin of Safety % (DCF Earnings Based) falls into.


FRA:HBI0
48GF Score
Harvard Bioscience Inc FRA:HBI0
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Harvard Bioscience (FRA:HBI0) Overvalued in 2026?

Based on GuruFocus' analysis, Harvard Bioscience stock appears to be undervalued. The current stock price of €4.08 is trading 69.3% below its estimated GF Value™ of €13.30.

Key valuation signals for FRA:HBI0:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: €13.30 vs. price of €4.08 (69.3% below fair value)
  • GF Score™: 48/100 with 6 warning signs

No single metric tells the full story. See the FRA:HBI0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Harvard Bioscience Business Description

Other Exchanges HBIO:USA
Address 84 October Hill Road, Suite 10, Holliston, MA, USA, 01746
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.
48GF Score

Get the complete analysis for FRA:HBI0

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.08
Price
€13.30
GF Value